Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

June 30, 2010

Study Completion Date

March 31, 2012

Conditions
Metabolic Syndrome XOverweightHypertensionDyslipidemiasPrediabetic State
Interventions
DRUG

Placebo Comparator: First Intervention (3 weeks)

once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells

DRUG

Active Comparator: Second Intervention (3 weeks)

Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells

DRUG

Active Comparator: Third Intervention (3 weeks)

Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells

DRUG

Active Comparator: Fourth Intervention (3 weeks)

Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells

Trial Locations (1)

63110

Washington University in St. Louis, St Louis

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Washington University School of Medicine

OTHER

NCT00455325 - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) | Biotech Hunter | Biotech Hunter